Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC (NCT05950139)

🧪 Interventions in This Study

• Peptide vaccine (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Johns Hopkins University — Baltimore, Maryland

📞 Contact the Study Coordinator

Phone: (410) 955-8964

Email: ThoracicCancerTrials@jhmi.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in NSCLC Stage IV

• Plasma-Adapted First-Line Pembro In NSCLC — Boston, Massachusetts
• Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC — Fairway, Kansas
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In — Springdale, Arkansas

Explore by condition: All NSCLC Stage IV clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.